Sio Gene Therapies Inc. (SIOX)
(Delayed Data from OTC)
$0.48 USD
0.00 (0.00%)
Updated Feb 7, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Sio Gene Therapies Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 65 | 119 | 81 |
Receivables | NA | NA | 2 | 6 | 2 |
Notes Receivable | NA | NA | 0 | 0 | 0 |
Inventories | NA | NA | 0 | 0 | 0 |
Other Current Assets | NA | NA | 5 | 7 | 3 |
Total Current Assets | NA | NA | 72 | 132 | 85 |
Net Property & Equipment | NA | NA | 1 | 0 | 1 |
Investments & Advances | NA | NA | 0 | 0 | 6 |
Other Non-Current Assets | NA | NA | 0 | 0 | 0 |
Deferred Charges | NA | NA | 0 | 0 | 0 |
Intangibles | NA | NA | 0 | 0 | 0 |
Deposits & Other Assets | NA | NA | 0 | 1 | 0 |
Total Assets | NA | NA | 75 | 135 | 94 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | 0 | 0 |
Accounts Payable | NA | NA | 4 | 1 | 4 |
Current Portion Long-Term Debt | NA | NA | 0 | 0 | 15 |
Current Portion Capital Leases | NA | NA | 0 | 0 | 0 |
Accrued Expenses | NA | NA | 8 | 9 | 11 |
Income Taxes Payable | NA | NA | 0 | 0 | 0 |
Other Current Liabilities | NA | NA | 0 | 0 | 0 |
Total Current Liabilities | NA | NA | 13 | 11 | 32 |
Mortgages | NA | NA | 0 | 0 | 0 |
Deferred Taxes/Income | NA | NA | 0 | 0 | 0 |
Convertible Debt | NA | NA | 0 | 0 | 0 |
Long-Term Debt | NA | NA | 0 | 0 | 0 |
Non-Current Capital Leases | NA | NA | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | NA | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | NA | 0 | 0 | 0 |
Total Liabilities | NA | NA | 15 | 12 | 32 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | 0 | 0 |
Common Stock (Par) | NA | NA | 0 | 0 | 0 |
Capital Surplus | NA | NA | 923 | 914 | 820 |
Retained Earnings | NA | NA | -863 | -791 | -759 |
Other Equity | NA | NA | 0 | 0 | 0 |
Treasury Stock | NA | NA | 0 | 0 | 0 |
Total Shareholder's Equity | NA | NA | 60 | 123 | 62 |
Total Liabilities & Shareholder's Equity | NA | NA | 75 | 135 | 94 |
Total Common Equity | 0 | 0 | 60 | 123 | 62 |
Shares Outstanding | NA | 72.90 | 72.90 | 47.20 | 36.80 |
Book Value Per Share | 0.00 | 0.00 | 0.83 | 2.61 | 1.67 |
Fiscal Year End for Sio Gene Therapies Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | -99,999 | -99,999 |
Receivables | NA | NA | NA | NA | NA |
Notes Receivable | NA | NA | NA | NA | NA |
Inventories | NA | NA | NA | NA | NA |
Other Current Assets | NA | NA | NA | NA | NA |
Total Current Assets | NA | NA | NA | NA | NA |
Net Property & Equipment | NA | NA | NA | NA | NA |
Investments & Advances | NA | NA | NA | NA | NA |
Other Non-Current Assets | NA | NA | NA | NA | NA |
Deferred Charges | NA | NA | NA | NA | NA |
Intangibles | NA | NA | NA | NA | NA |
Deposits & Other Assets | NA | NA | NA | NA | NA |
Total Assets | NA | NA | NA | NA | NA |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | NA |
Accounts Payable | NA | NA | NA | NA | NA |
Current Portion Long-Term Debt | NA | NA | NA | NA | NA |
Current Portion Capital Leases | NA | NA | NA | NA | NA |
Accrued Expenses | NA | NA | NA | NA | NA |
Income Taxes Payable | NA | NA | NA | NA | NA |
Other Current Liabilities | NA | NA | NA | NA | NA |
Total Current Liabilities | NA | NA | NA | NA | NA |
Mortgages | NA | NA | NA | NA | NA |
Deferred Taxes/Income | NA | NA | NA | NA | NA |
Convertible Debt | NA | NA | NA | NA | NA |
Long-Term Debt | NA | NA | NA | NA | NA |
Non-Current Capital Leases | NA | NA | NA | NA | NA |
Other Non-Current Liabilities | NA | NA | NA | NA | |
Minority Interest (Liabilities) | NA | NA | NA | NA | NA |
Total Liabilities | NA | NA | NA | NA | NA |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | NA |
Common Stock (Par) | NA | NA | NA | NA | NA |
Capital Surplus | NA | NA | NA | NA | NA |
Retained Earnings | NA | NA | NA | NA | NA |
Other Equity | NA | NA | NA | NA | NA |
Treasury Stock | NA | NA | NA | NA | NA |
Total Shareholder's Equity | NA | NA | NA | NA | NA |
Total Liabilities & Shareholder's Equity | NA | NA | NA | NA | NA |
Total Common Equity | 0 | 0 | 0 | 0 | 0 |
Shares Outstanding | NA | NA | NA | 72.90 | 72.90 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |